TFAP2A and gastric cancer: In the molecular mechanism study, we also found that EGCG suppressed the expression of both MDR-1and P-gp drug-resistance related proteins at mRNA and protein level in vivo and in vitro, Western blot and ELISA assay revealed that EGCG was able to inhibit VEGF secretion and the expression of transcription factor activator protein 2A phosphorylation, indicating that TFAP2A/VEGF axis was inhibited by EGCG for gastric cancer cell proliferation and 5-FU resistance.